Author
Harvard UniversityORCID 0000-0001-5344-6645Unclaimed ORCID profile · follow to get notified of new preprints
Mutual co-authors in cluster
6 papers
Recent·Most cited
Hongyan Xie, Aiping Jiang, Aonkon Dey…·Russell William Jenkins
This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.
Jiekun Yang, Cassia Wang, Doris Fu…·Manolis Kellis
The paper identifies a mature dendritic cell subtype associated with improved immune response and prognosis in melanoma patients treated with anti-PD-1 checkpoint inhibitors.
Or‐Yam Revach, Angelina M. Cicerchia, Ofir Shorer…·Russell William Jenkins
This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.
Avanish Mishra, Shih‐Bo Huang, Taronish D. Dubash…·Mehmet Toner
This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.
S N Wei, Kuang Du, Hongbin Lan…·Gao Zhang
This study identifies molecular mechanisms of resistance to immune checkpoint blockade in metastatic melanoma using proteogenomic and spatial analyses of tumor and immune microenvironment data.
Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim…·Nir Hacohen
The paper develops DNA- and RNA-based models combining immune and tumor features to predict outcomes of checkpoint inhibition in melanoma.